Chemistry:Motexafin gadolinium

From HandWiki
Revision as of 14:50, 26 June 2023 by Jport (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Motexafin gadolinium
Motexafin gadolinium 3D sticks.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC52H72GdN5O14
Molar mass1148.42 g·mol−1
3D model (JSmol)
  (verify)

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]

History

On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]

In December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]

References